UK REACH Authorisation List (Annex 14)

Hexavalent chromium (Cr VI) Authorisations

EU granted authorisations covering EU and GB supply chains after 21 September 2024 – more information

List of substances in Annex 14 of UK REACH (Authorisation List).

Document

UK REACH Authorisation List (Annex 14)

Document type
Excel, 19kb

Detail

The authorisation provisions of UK REACH aim to ensure that substances of very high concern (SVHCs) are progressively replaced by less dangerous substances or technologies where feasible alternatives exist.

Substances that have been identified as SVHCs and included in the Authorisation List (Annex 14) cannot be used or placed on the market for a use after a specified date, known as the sunset date, unless the use has been authorised or is exempt from authorisation.

Applying for a UK REACH authorisation

In accordance with Article 58(3) of UK REACH, HSE is required to recommend priority substances for inclusion in this list from the UK REACH Candidate List of substances of very high concern (SVHCs).

Notes for the authorisation list

Annex 14 of UK REACH is a copy of Annex XIV of EU REACH as it stood at the end of the transition period and the same latest application dates and sunset dates apply, except for entries 44 to 54 whose latest application dates are 30 June 2022 (Article 127GA (7)&(8)).

Entries Notes

4 to 7
10 to 12
14 to 23
25
27 to 46

In 'Latest application date' column - 1 September 2021 for the use of the substance in the production of spare parts as articles or as complex products for the repair of articles or complex products, the production of which ceased or will have ceased before the sunset date indicated in the entry for that substance, where that substance was used in the production of those articles or complex products and these cannot function as intended without that spare part and the spare part cannot be produced without that substance, and for the use of the substance (on its own or in a mixture) for the repair of such articles or complex products where that substance on its own or in a mixture was used in the production of those articles or complex products and they cannot be repaired otherwise than by using that substance

In 'Sunset date' column - 1 March 2023 for the use of the substance in the production of spare parts as articles or as complex products for the repair of articles or complex products, the production of which ceased or will have ceased before the sunset date indicated in the entry for that substance, where that substance was used in the production of those articles or complex products and these cannot function as intended without those spare parts and the spare part cannot be produced without that substance, and for the use of the substance (on its own or in a mixture) for the repair of such articles or complex products where that substance on its own or in a mixture was used in the production of those articles or complex products and they cannot be repaired otherwise than by using that substance

40

Does not meet the criteria for identification as a carcinogen if it contains < 0,005 % (w/w) benzo[a]pyrene (Einecs No 200-028-5)

42

In ‘Latest application date’ column, 22 June 2022 for uses as follows:

  • for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746 of the European Parliament and of the Council (Regulation (EU) 2017/746 of the European Parliament and of the Council of 5 April 2017 on in vitro diagnostic medical devices and repealing Directive 98/79/EC and Commission Decision 2010/227/EU (OJ L 117, 5.5.2017, p. 176)), in view of their use for the diagnosis, treatment or prevention of the coronavirus disease (COVID-19)
  • in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19.

In ‘Sunset date’ column, 22 December 2023 for uses as follows:

  • for the research, development and production of medicinal products falling within the scope of Directive 2001/83/EC or medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, in view of their use for the diagnosis, treatment or prevention of COVID-19
  • in medical devices or accessories to medical devices falling within the scope of Directive 93/42/EEC, Regulation (EU) 2017/745, Directive 98/79/EC or Regulation (EU) 2017/746, for the diagnosis, treatment or prevention of COVID-19.

Is this page useful?

Updated 2024-09-20